WAVEMAN · COMPANY

REGN · Regeneron Pharmaceuticals, Inc.

LIVE

TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475

← ALL COMPANIES

REGN

Name: REGENERON PHARMACEUTICALS, INC. (REGN) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

REGENERON PHARMACEUTICALS, INC.

PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0000872589

CONGRESS · 2FORM 144 · 6☆ WATCH

INSIDER NET · 180D

-$3.6M

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

612

13F, latest reported quarter

REVENUE GROWTH

+1.0%

XBRL, annual

NET MARGIN

31.4%

CONVERSIONS · 180D

codes C/M, not in net · $8.0M priced

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net -$3.6M over 180 days

-$3.4M over 90 days

below 74% of Pharma & Biotech

CONGRESS

2 members bought in the last year

more than 65% of Pharma & Biotech

FUNDS

612 funds added or opened last quarter

more than 98% of Pharma & Biotech

REVENUE

+1.0% year over year

below 52% of Pharma & Biotech

MARGIN

31.4% net margin

more than 92% of Pharma & Biotech

BUYBACKS

$2.0B repurchased, FY to 2026-06-30

more than 98% of Pharma & Biotech

SHORT

no short interest reported

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

Insiders are net sellers: -$3.6M across 4 people in 180 days.

612 funds added or opened positions in the latest 13F quarter, of 1,342 holders.

2 members of Congress reported buying it this year.

1 clinical trial was terminated, suspended or withdrawn in the last 90 days.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN +48.0%

+48.0%12M

INSIDER SELLFORM 144

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

Insiders have filed to sell — before selling.

The record shows a net $3.6M sold by insiders over 180 days, 612 funds added last quarter, 2 Congress member(s) bought in 12 months, $3.6M in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA LLY ALNY ELF CITR MDGL DNA VRTX NUVL INSM

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, REGENERON PHARMACEUTICALS, INC. insiders sold a net $3.6M of stock across 1,353 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-04.

INSIDER

FILED

VALUE

McCourt Marion

EVP Commercial

SELL

2026-09-03

1,131.0

$969.7K

Guarini Kathryn

Director

SELL

2026-09-02

400.0

$340.0K

McCourt Marion

EVP Commercial

SELL

2026-09-02

1,215.0

$1.0M

Zoghbi Huda Y

Director

SELL

2026-08-10

800.0

$640.0K

Guarini Kathryn

Director

SELL

2026-08-10

400.0

$320.0K

1,353 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 1,348 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

BlackRock, Inc.

9,113,506.0 sh

$5.7B

VANGUARD CAPITAL MANAGEMENT LLC

6,629,759.0 sh

$4.1B

Dodge & Cox

4,871,137.0 sh

$3.0B

STATE STREET CORP

4,834,688.0 sh

$3.0B

Invesco Ltd.

3,940,665.0 sh

$2.5B

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

Planned sales · Form 144

Filed before the sale — intent, not a trade

McCourt Marion

FILED 2026-09-03

$969.3K

Guarini Kathryn

FILED 2026-09-02

$340.0K

McCourt Marion

FILED 2026-09-02

$1.0M

Guarini Kathryn

FILED 2026-08-10

$320.0K

Zoghbi Huda Y

FILED 2026-08-10

$640.0K

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

VanEck Biotech ETF

$27.9M POSITION · AS OF 2026-03-31

7.5%

iShares Biotechnology ETF

$585.8M POSITION · AS OF 2026-03-31

7.2%

Invesco Nasdaq Biotechnology ETF

$4.6M POSITION · AS OF 2026-02-28

6.0%

Nomura Healthcare Fund

$36.3M POSITION · AS OF 2026-03-31

5.5%

Longleaf Partners Global Fund

$31.9M POSITION · AS OF 2026-03-31

4.8%

Longleaf Partners Fund

$50.6M POSITION · AS OF 2026-03-31

4.8%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Clinical pipeline

ClinicalTrials.gov · 244 registered trials, 115 still enrolling or running — a status change here is dated weeks before the press release

Phase 1

17 ACTIVE

Phase 2

25 ACTIVE

Phase 3

34 ACTIVE

Phase 4

4 ACTIVE

Not applicable

11 ACTIVE

Multi-phase

24 ACTIVE

What changed recently

Study of Bet v1 Antibodies Effect on Eye Allergy Symptoms in Adolescents and Adults With

2026-09-02 · Recruiting → Terminated · Sponsor Decision

Phase 3

A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutid

2026-09-02 · Completion moved 2026-05-06 → 2026-06-16

Phase 2

Compassionate Use or Expanded Access of Dupilumab

2026-09-02 · Approved For Marketing → Available

—

TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED

Government contracts

USASpending.gov · total award ceilings over the contract's life, including awards won through subsidiaries — not annual revenue

Department Of Health And Human Services

IGF::OT::IGF · 2017-09-30

$695.7M

FEDERAL AWARDS ≥ $25M IN THE LAST 90 DAYS · MATCHED VIA SAM.GOV PARENT REGISTRY

Corporate PAC

FEC · the company-connected political action committee's own receipts and spending — committee totals only, never individual donors

Regeneron Pharmaceuticals, Inc. Pac

CYCLE 2026 · $160K SPENT

$261.5K

FEDERAL ELECTION COMMISSION · MATCHED BY THE PAC'S CONNECTED ORGANISATION

Executive pay vs shareholder return · Leonard S. Schleifer

DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself

CEO TOTAL

ACTUALLY PAID

OTHER NEOs AVG

TSR

PEER TSR

2025

$7.3M

$39.0M

$7.7M

+60%

+101%

2024

$6.8M

-$37.7M

$6.1M

+47%

+56%

2023

$8.2M

$141.1M

$6.7M

+82%

+44%

2022

$7.0M

$98.8M

$8.1M

+49%

+39%

2021

$6.5M

$123.7M

$7.5M

+31%

+24%

TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$14.3B	$14.2B	$13.1B	$12.2B
OPERATING INCOME	$3.6B	$4.0B	$4.0B	$4.7B
NET INCOME	$4.5B	$4.4B	$4.0B	$4.3B
EPS (DILUTED)	41.48	38.34	34.77	38.22
OPERATING CASH FLOW	$5.0B	$4.4B	$4.6B	$5.0B
CASH	$3.1B	$2.5B	$2.7B	$3.1B
LONG-TERM DEBT	$2.0B	$2.0B	$2.0B	$2.0B
BUYBACKS	$3.4B	$2.6B	$2.2B	$2.1B
DIVIDENDS PAID	$370.3M	$0	$0	—

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-04 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE